5-amino-4-cyano-1-(β-phenylethyl)pyrazole | 159979-74-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-amino-4-cyano-1-(β-phenylethyl)pyrazole
• 英文别名: 5-amino-1-phenethyl-1H-pyrazole-4-carbonitrile；4-cyano-5-amino-1-(2-phenylethyl)pyrazole；1-phenethyl-4-cyano-5-aminopyrazole；5-amino-1-(2-phenylethyl)-1H-pyrazole-4-carbonitrile；5-amino-1-(2-phenylethyl)pyrazole-4-carbonitrile
• CAS: 159979-74-5
• 化学式: C₁₂H₁₂N₄
• 分子量: 212.254
• InChiKey: FGWVIQWGHLKUCM-UHFFFAOYSA-N

物化性质

• 沸点：
  444.4±40.0 °C(Predicted)
• 密度：
  1.19±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  67.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-amino-4-cyano-1-(β-phenylethyl)pyrazole 在 N-甲基吡咯烷酮 、 盐酸 、 对甲苯磺酸 作用下， 以 二苯醚 、 乙二醇甲醚 为溶剂， 反应 12.5h， 生成 2-(2-呋喃基)-7-(2-苯基乙基)-7H-吡唑并[4,3-e][1,2,4]噻唑并[1,5-c]嘧啶-5-胺
  参考文献：
  名称：

  Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine Derivatives:  Potent and Selective A_2A Adenosine Antagonists

  摘要：

  A series of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives (10a-o,q,r), bearing alkyl and aralkyl chains on positions 7 and 8, were synthesized in the attempt to obtain potent and selective antagonists for the A(2A) adenosine receptor subtype. The compounds were tested in binding and functional assays to evaluate their potency for the A(2A) compared with the A(1) adenosine receptor subtype. In binding studies in rat brain membranes, most of the compounds showed affinity for A(2A) receptors in the low nanomolar range with a different degree of A(2A) versus A(1) selectivity. Comparison of N-7 (10a-d,h-o)- and N-8 (10e-g)-substituted pyrazolo derivatives indicates that N-7 substitution decreases the A(1) affinity with the concomitant increase of A(2A) selectivity. Specifically, the introduction of a 3-phenylpropyl group at pyrazolo nitrogen in position 7 (101) increased significantly the A(2A) selectivity, being 210-fold, while the A(2A) receptor affinity remained high (K-i = 2.4 nM). With regards to the affinity for A(2A) receptors, also the compound 10n, bearing in the 7-position a beta-morpholin-4-ylethyl group, deserves attention (K-i = 5.6 nM) even though the A(2A) selectivity (84-fold) was not as high as that of 101. Conversely, the compound 10m (N-7-4-phenylbutyl derivative) showed a remarkable selectivity (A(1)/A(2A) ratio = 129) associated with lower A(2A) affinity (K-i = 21 nM). In functional studies, most of the compounds examined reversed 5'-(N-ethylcarbamoyl)adenosine-induced inhibition of rabbit platelet aggregation inhibition which is a biological response mediated by the A(2A) receptor subtype. The compounds are potent and selective A(2A) antagonists which can be useful to elucidate the pathophysiological role of this adenosine receptor subtype. These compounds deserve to be further developed to assess their potential for treatment of neurodegenerative disorders such as Parkinson's disease.

  DOI：

  10.1021/jm950746l
• 作为产物：
  描述：

  乙氧基亚甲基丙二腈 、 苯乙肼 以 乙醇 为溶剂， 以56%的产率得到5-amino-4-cyano-1-(β-phenylethyl)pyrazole
  参考文献：
  名称：

  酪氨酸激酶抑制剂CLM3的基于结构的优化。设计，合成，功能评估和分子建模研究。

  摘要：

  甲状腺癌发展知识的最新进展将受体酪氨酸激酶（如VEGFR2和RET）确定为可行且有希望的靶标。因此，它们的抑制作用正在成为治疗这些病理的主要治疗策略。在这项研究中，我们描述了三个不同系列的4-取代的吡唑并[3,4- d ]嘧啶衍生物8a – g，9a – g和10a – g的合成和功能评估，它们是基于结构优化设计的先前开发的抑制剂CLM3。与铅相比，新化合物显着改善了它们对靶蛋白，VEGFR2和RET的抑制特性，以及它们对甲状腺髓样癌细胞系TT的抗增殖功效。值得注意的是，化合物8b，9c和10c被证明可以阻断仍然缺乏有效抑制剂的RET V804L突变体的激酶活性。

  DOI：

  10.1021/jm401358b

文献信息

• Design, Synthesis, and Biological Evaluation of C⁹- and C²-Substituted Pyrazolo[4,3-<i>e</i>]-1,2,4-triazolo[1,5-<i>c</i>]pyrimidines as New A_2A and A₃ Adenosine Receptors Antagonists
  作者：Pier Giovanni Baraldi、Francesca Fruttarolo、Mojgan Aghazadeh Tabrizi、Delia Preti、Romeo Romagnoli、Hussein El-Kashef、Allan Moorman、Katia Varani、Stefania Gessi、Stefania Merighi、Pier Andrea Borea

  DOI：10.1021/jm021023m

  日期：2003.3.1

  C(2)-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines to represent an extension of structure-activity relationship work on this class of tricyclic compounds. The introduction of a substituent at 9 position of the tricyclic antagonistic structure led to retention of receptor affinity but a loss of selectivity in respect to the lead compounds b, N(8)-substituted-pirazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines-N(5)-urea

  在过去的几年中，我们小组一直致力于A（2A）和A（3）腺苷受体拮抗剂的开发，从而导致了SCH58261（5-氨基-7-（2-苯乙基）-2-（ 2-furyl）pyrazolo [4,3-e] -1,2,4-triazolo [1,5-c] pyrimi dine，61），对A（2A）受体亚型和N（8 ）-取代的吡唑并[4,3-e] -1,2,4-三唑并[1,5-c]嘧啶-N（5）-脲或酰胺（MRE系列，b），对人A的选择性很高（3）腺苷受体亚型。我们现在描述一系列由C（9）-和C（2）取代的吡唑并[4,3-e] -1,2,4-三唑并[1,5-c]嘧啶，以代表结构的扩展-这类三环化合物之间存在活性关系。在三环拮抗结构的9位上引入取代基导致保留受体亲和力，但相对于先导化合物b，N（8）-取代的吡唑并[4,3-e] -1，失去了选择性， 2,4-三唑并[1,5-c]嘧啶-N（5）-脲或-酰胺。受
• Adenosine A3 receptor modulators
  申请人：——

  公开号：US20030144266A1

  公开（公告）日：2003-07-31

  The compounds of the following formula: 1 wherein R, R 2 , R 3 and A have the meanings given in the specification, are endowed with selective A 3 adenosine receptor antagonist activity. These compounds can be used in a pharmaceutical composition to treat disorders caused by excessive activation of the A 3 receptor, or can be used in a diagnostic application to determine the relative binding of other compounds to the A 3 receptor. The compounds can be labeled, for example with fluorescent or radiolabels, and the labels used in vivo or in vitro to determine the presence of tumor cells which possess a high concentration of adenosine A 3 receptors.

  具有以下公式的化合物：其中R、R2、R3和A具有规范中给定的含义，具有选择性A3腺苷受体拮抗活性。这些化合物可以用于制备药物组合物，用于治疗由A3受体过度激活引起的疾病，也可以用于诊断应用，以确定其他化合物与A3受体的相对结合。这些化合物可以被标记，例如用荧光标记或放射性标记，并且这些标记可以在体内或体外用于确定具有高浓度腺苷A3受体的肿瘤细胞的存在。
• Organoruthenium Antagonists of Human A₃Adenosine Receptors
  作者：Priyankar Paira、Mun Juinn Chow、Gopalakrishnan Venkatesan、Vamsi Krishna Kosaraju、Siew Lee Cheong、Karl-Norbert Klotz、Wee Han Ang、Giorgia Pastorin

  DOI：10.1002/chem.201203291

  日期：2013.6.17

  triazolo moiety with an organoruthenium fragment. The objective was to introduce by design structural diversity into the PTP scaffold in order to tune their binding efficacy toward the target receptor. These novel organoruthenium antagonists displayed good aquatic stability and moderate binding affinity toward the hA3 receptor in the low micromolar range. The assembly of these complexes through a template‐driven

  人A 3腺苷受体（hA 3 AR）是膜结合的G蛋白偶联受体，与许多严重的病理状况（包括癌症）有关，在其中它可能成为潜在的治疗靶标。为了推导基于吡唑并三唑并嘧啶（PTP）的A 3 AR拮抗剂的构效关系，我们通过用有机钌片段代替三唑并开发了新型的有机金属抑制剂。目的是通过设计将结构多样性引入PTP支架中，以调节其对靶受体的结合功效。这些新型的有机钌拮抗剂显示出良好的水生稳定性和对hA 3的中等结合亲和力受体在低微摩尔范围内。讨论了通过模板驱动的方法组装这些复合物，并在金属中心进行选择性配体置换以控制其空间和受体结合特性的方法。
• Antimicrobial and antitumor activity of n-heteroimmine-1,2,3-dithiazoles and their transformation in triazolo-, imidazo-, and pyrazolopirimidines
  作者：Pier Giovanni Baraldi、Maria Giovanna Pavani、Maria del Carmen Nuñez、Patrizia Brigidi、Beatrice Vitali、Roberto Gambari、Romeo Romagnoli

  DOI：10.1016/s0968-0896(01)00294-2

  日期：2002.2

  sodium methoxide in refluxing methanol. This provides a general and attractive route to 4-methoxy-6-cyano pyrazolo[3,4-d]pyrimidines from 1-substituted 5-amino pyrazoles 10-19 in two simple steps. Finally, the isosteric replacement of the pyrazole ring atoms to give the imidazole[3,4-d]pyrimidine and triazole [4,5-d] pyrimidine ring systems was examined.

  Appel盐与邻氨基腈杂环10-19的反应得到相应的4-氯-5-杂亚胺-1,2,3-二噻唑20-29，对其抗菌，抗真菌和抗肿瘤活性进行了评估。尽管所有这些N-杂亚胺都没有显着的抗菌活性，但它们显示出显着的抗真菌活性。而且，相同的衍生物代表了杂环合成中的通用中间体，实际上，吡唑亚氨基二噻唑20-26可以一步转化为相应的4-甲氧基-吡唑并[3,4-d]嘧啶30-的2-氰基衍生物。 35由甲醇钠在甲醇中回流。这提供了通过两个简单的步骤从1-取代的5-氨基吡唑10-19生成4-甲氧基-6-氰基吡唑并[3,4-d]嘧啶的一般且有吸引力的途径。最后，
• Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpurines
  作者：Roger J. Gillespie、Ian A. Cliffe、Claire E. Dawson、Colin T. Dourish、Suneel Gaur、Allan M. Jordan、Antony R. Knight、Joanne Lerpiniere、Anil Misra、Robert M. Pratt、Jonathan Roffey、Gemma C. Stratton、Rebecca Upton、Scott M. Weiss、Douglas S. Williamson

  DOI：10.1016/j.bmcl.2008.03.072

  日期：2008.5

  A series of pyrazolo[3,4-d]pyrimidine, pyrrolo[2,3-d]pyrimidine and 6-arylpurine adenosine A(2A) antagonists is described. Many examples were highly selective against the human A(1) receptor sub-type and were active in an in vivo model of Parkinson's disease.

  描述了一系列的吡唑并[3,4-d]嘧啶，吡咯并[2,3-d]嘧啶和6-芳基嘌呤腺苷A（2A）拮抗剂。许多示例对人类A（1）受体亚型具有高度选择性，并且在帕金森氏病的体内模型中具有活性。